Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alnylam to Webcast Presentations at Upcoming Investor Conferences

11/23/2021 | 08:01am EST

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

  • Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 9:40 am ET
  • Piper Sandler 33rd Annual Virtual Healthcare Conference on Thursday, December 2, 2021 at 10:00 am ET

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), as well as Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.


ę Business Wire 2021
All news about ALNYLAM PHARMACEUTICALS, INC.
01/21Health Care Stocks Decline Pre-Bell Friday
MT
01/21Alnylam Pharmaceuticals Says Vutrisiran Met All Secondary Endpoints from HELIOS-A Phase..
MT
01/21Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigation..
BU
01/21Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigation..
CI
01/20HC Wainwright Boosts Price Target on Alnylam Pharmaceuticals to $350 From $250, Keeps B..
MT
01/18Morgan Stanley Adjusts Alnylam Pharmaceuticals' Price Target to $215 from $226, Keeps O..
MT
01/17Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
AQ
01/14Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
BU
01/14Alnylam Pharmaceuticals, Inc. to Present Full 18-Month Results from the HELIOS-A Phase ..
CI
01/10Alnylam Announces Preliminary Fourth Quarter and Full Year 2021 Global Net Product Reve..
AQ
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 821 M - -
Net income 2021 -760 M - -
Net cash 2021 1 321 M - -
P/E ratio 2021 -21,2x
Yield 2021 -
Capitalization 16 315 M 16 315 M -
EV / Sales 2021 18,3x
EV / Sales 2022 12,1x
Nbr of Employees 1 453
Free-Float 99,4%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 136,41 $
Average target price 211,33 $
Spread / Average Target 54,9%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet President, Chief Operating Officer & Director
Akshay K. Vaishnaw President-Research & Development
Jeffrey V. Poulton Executive VP, Chief Financial & Accounting Officer
Michael W. Bonney Independent Director
Pushkal Garg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-19.56%16 315
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508